Cancer Medicine (Feb 2024)

A meta‐analysis comparing efficacy and safety between proton beam therapy versus carbon ion radiotherapy

  • Jeong Yun Jang,
  • Kangpyo Kim,
  • Miao‐Fen Chen,
  • Tetsuo Akimoto,
  • Michael Lian Chek Wang,
  • Min‐Ji Kim,
  • Kyunga Kim,
  • Tae Hoon Lee,
  • Gyu Sang Yoo,
  • Hee Chul Park

DOI
https://doi.org/10.1002/cam4.7023
Journal volume & issue
Vol. 13, no. 3
pp. n/a – n/a

Abstract

Read online

Abstract Background This study aimed to compare the outcomes of proton beam therapy (PBT) and carbon ion radiotherapy (CIRT) by a systematic review and meta‐analysis of the existing clinical evidence. Methods A systematic literature search was performed to identify studies comparing the clinical outcomes of PBT and CIRT. The included studies were required to report oncological outcomes (local control [LC], progression‐free survival [PFS], or overall survival [OS]) or adverse events. Results Eighteen articles comprising 1857 patients (947 treated with PBT and 910 treated with CIRT) were included in the analysis. The pooled analysis conducted for the overall population yielded average hazard ratios of 0.690 (95% confidence interval (CI), 0.493–0.967, p = 0.031) for LC, 0.952 (95% CI, 0.604–1.500, p = 0.590) for PFS, and 1.183 (0.872–1.607, p = 0.281) for OS with reference to CIRT. The subgroup analyses included patients treated in the head and neck, areas other than the head and neck, and patients with chordomas and chondrosarcomas. These analyses revealed no significant differences in most outcomes, except for LC in the subgroup of patients treated in areas other than the head and neck. Adverse event rates were comparable in both groups, with an odds ratio (OR) of 1.097 (95% CI, 0.744–1.616, p = 0.641). Meta‐regression analysis for possible heterogeneity did not demonstrate a significant association between treatment outcomes and the ratio of biologically effective doses between modalities. Conclusion This study highlighted the comparability of PBT and CIRT in terms of oncological outcomes and adverse events.

Keywords